Edwards Lifesciences Corp (EW) 153.96 $EW
The Best Stocks in Medical Devices Are Kicking It Overseas
Cheryl Swanson, The Motley Fool - Motley Fool - 36 mins ago
Source: Flickr/Anders Sandher. Looking for medical-device stocks with solid fundamentals and long-term growth drivers? Then train your eyes overseas. With apologies to Shakespeare, the world is the medical-device industry's new oyster. While...
MDT: 77.19 (+1.53), EW: 153.96 (+1.24)
5 Health Care Stocks to Trade for Gains -- Must-See Charts
at The Street - 50 mins ago
Health care stocks have been persistent outperformers in 2015. Here are five to trade now.
GILD: 112.79 (+2.25), UTHR: 168.27 (+2.49), SHPG: 262.93 (+3.82), EW: 153.96 (+1.24), IDXX: 65.67 (-0.63)
Edwards Lifesciences Set to Possibly Rebound After Yesterday's Selloff of 1.53%
Comtex SmarTrend(R) - Mon Jul 27, 5:15PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $151.90 to a high of $154.75. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $154.70 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EW: 153.96 (+1.24)
Meet 5 IBD 50 Stocks Reporting Earnings This Week
at Investor's Business Daily - Sat Jul 25, 9:02AM CDT
Earnings season has kicked into high gear, and a number of top-rated stocks such as Vasco Data Security (VDSI) and Facebook (FB) are due to report earnings this coming week. The computer-generated IBD 50 list of premier stocks is based on a...
VDSI: 25.62 (+0.50), ELLI: 70.59 (-1.04), GILD: 112.79 (+2.25), FB: 94.89 (+0.72), ORLY: 241.48 (+1.64), UTHR: 168.27 (+2.49), EW: 153.96 (+1.24), CRI: 108.41 (+1.71), TASR: 30.59 (+0.26)
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market
at Investor's Business Daily - Fri Jul 24, 6:14PM CDT
A handful of IBD 50 stocks got a boost last week, bucking overall market weakness, thanks to better-than-expected quarterly results. Illumina (ILMN), which makes genetic testing equipment, was among the few disappointments. It plunged 8% Wednesday...
VRX: 257.53 (+0.23), ELLI: 70.59 (-1.04), FB: 94.89 (+0.72), UHS: 141.22 (+0.93), UTHR: 168.27 (+2.49), ORLY: 241.48 (+1.64), EW: 153.96 (+1.24), ILMN: 217.61 (+0.34), MANH: 64.38 (-0.57), SBUX: 57.10 (+0.12), VDSI: 25.62 (+0.50), CRUS: 34.08 (+1.18), TASR: 30.59 (+0.26), AAPL: 123.47 (+0.70)
New Cardiac Devices Get Investors' Hearts Pumping
at Investor's Business Daily - Fri Jul 24, 2:16PM CDT
A hot new technology. A widespread, deadly disease. A whole lot of money changing hands. That was the story last Wednesday when St. Jude Medical (STJ) agreed to pay $3.4 billion in cash for Thoratec (THOR), developer of an implant called the left...
BSX: 17.42 (+0.31), ABT: 50.97 (+0.28), ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), CAH: 83.34 (+1.05), LMAT: 11.22 (+0.01), EW: 153.96 (+1.24), STJ: 74.04 (+0.86), THOR: 63.07 (-0.16), VASC: 38.03 (-0.10), HTWR: 81.08 (-1.67), MMSI: 25.64 (+0.46)
The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters) to 2019
M2 - Fri Jul 24, 8:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8qwd2/the_world_market) has announced the addition of the "The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters)" report to their offering. Among the catheters used in urological applications are the Foley and the urethral catheters. Cardiovascular catheters find use in cardiac catheterization. Angiography catheters are used in cardiological diagnostics. Intravenous catheters are used if a person requires frequent or continuous injections of medications or fluids for nutritional support. A wound drain catheter is inserted while a patient is in the operating room receiving general anesthesia All of these catheters are included in this report. For many of these segments, company market share and regional breakout for US, Europe and Rest of World is provided. In addition to numbers that can be useful for business planning, the report provides analysis of the industry, including analysis of several important trends. Increased life expectancy and subsequent aging of the global population play a key role in the rising demand for all types of medical catheters. Companies seeking opportunities in this medical device market will want to utilize Kalorama Information's World Market for Catheters. This report contains global market size and forecast to 2019 for the following types of catheters: - Foley Catheters - Urethral Catheters - PTCA Catheters - Dialysis Catheters - Atherectomy Catheters - Ablation Catheters - Cardiac Angiography Catheters - Peripheral Angiography Catheters - Implantable Ports - Central Venous Catheters - Peripheral Insertion Catheters - Peripherally Inserted Central Catheters - Peripheral Insertion Midline Catheters - Oximetry Catheters - Thermodilution Catheters - Suction Catheters - Wound Drainage Catheters Trends discussed in this report include the following: - Infection and Control - Vascular - Urinary - Catheter Intervention Trends - Catheter Malfunction - Antimicrobial Lock Solutions - Stroke Treatment - MRI Catheters - Sinus Balloon Catheter - Interventional Radiology - Heart Patch - PFO - New And Alternative Materials - Antiseptic-Coated Catheters Company profiles are included, with profiles of the following companies: - Abbott Laboratories - Angio Dynamics - Atrium Medical - Bactiguard Ab - C.R. Bard - Becton Dickinson - Boston Scientific - B. Braun Melsungen - Cardinal Health - Carmeda - Cook Group - Catheter Research Inc. - Covidien - Edwards Lifesciences - Greatbatch Medical - Johnson &Johnson - Flexicath - Hansen Medical - Iapyx Medical - Integra Lifesciences Holdings - Irvine Scientific - Medtronic - Medcomp - Siemens Medical Solutions - Smiths Medical - St.Jude Medical - Teleflex Medical Company - Terumo - Vascular Solutions - Vesta Inc. - Volcano Corp. - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/v8...rld_market
ZMH: 113.56 (+0.29), BSX: 17.42 (+0.31), ABT: 50.97 (+0.28), MDT: 77.19 (+1.53), HNSN: 0.88 (-0.02), VOLC: 17.99 (+0.01), EW: 153.96 (+1.24), VASC: 38.03 (-0.10)
What's in Store for Edwards Lifesciences (EW) in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 5:14PM CDT
Last quarter, Edwards Lifesciences (EW) had delivered a positive earnings surprise of 7.69%
ZLTQ: 32.26 (+0.89), EW: 153.96 (+1.24), AMED: 43.79 (+0.35), XRAY: 52.13 (+0.53)
Breakout Watch: Abiomed Pumps Up Before Earnings
at Investor's Business Daily - Thu Jul 23, 10:39AM CDT
Heart pump maker Abiomed (ABMD) is closing in on a buy point as it gets ready to report Q2 earnings Aug. 4. With a mission of "recovering hearts and saving lives," Abiomed developed the Impella 2.5, which it bills as the world's smallest heart pump....
ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), STJ: 74.04 (+0.86), EW: 153.96 (+1.24), THOR: 63.07 (-0.16)
SmarTrend Watching for Potential Pullback in Shares of Edwards Lifesciences After 1.35% Gain
Comtex SmarTrend(R) - Tue Jul 21, 4:44PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $153.82 to a high of $156.49. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $155.03 on volume of 909,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 153.96 (+1.24)
Cramer Says Investors Who Missed Google, Facebook, Netflix Runs Now Have to Wait
at The Street - Tue Jul 21, 4:24PM CDT
Jim Cramer answered viewers' Twitter questions on matters including popular stocks, commodities and gold.
ABMD: 73.05 (+0.33), FB: 94.88 (+0.71), GOLD: 59.28 (+1.69), EW: 153.96 (+1.24), GOOG: 627.05 (-0.21), NFLX: 107.53 (+1.10), T: 34.38 (+0.06), STJ: 74.04 (+0.86), TMUS: 36.99 (+0.49), TWTR: 35.95 (+1.25), VZ: 45.82 (-0.01), AAPL: 123.47 (+0.70)
Edwards Lifesciences Shares Up 16.6% Since SmarTrend's Buy Recommendation (EW)
Comtex SmarTrend(R) - Tue Jul 21, 11:01AM CDT
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on June 9th, 2015 at $133.64. In approximately 1 month, Edwards Lifesciences has returned 16.61% as of today's recent price of $155.84.
EW: 153.96 (+1.24)
Global Clot Management Devices Market 2015-2019 with AngioDynamics, Boston Scientific, Cook Group & Stryker Dominating
M2 - Mon Jul 20, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xm9gtt/global_clot) has announced the addition of the "Global Clot Management Devices Market 2015-2019" report to their offering. The global clot management devices market to grow at a CAGR of 5.95% over the period 2014-2019. A blood clot or thrombus is the end stage of blood coagulation process in hemostasis. Blood clot is the body's response to an injury to prevent bleeding. However, a clot can be harmful when it forms abnormally to obstruct blood flow through healthy blood vessels. This condition is called thrombosis. A blood clot in arteries can lead to heart attack, while blood clot formed in the deep veins can lead to DVT or PE. Clot management devices help in the removal of a clot or dissolving clot in the blood vessels. The report, the Global Clot Management Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it also covers the global clot management devices market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. One of the trends is the increased number of MIS procedures. Surgical procedures expose a patient's blood to foreign surfaces, which may initiate coagulation. DVT and PE are some major complications faced by patients who undergo surgery. MIS reduces patient trauma and recovery time. According to the report, a rise in awareness of endovascular treatment is one of the primary drivers in this market. Endovascular treatment is a surgical treatment in which microcatheters, embolic coils, and stents are used to remove blood clots. Further, the report states that the high acceptance of anticoagulant therapy is hindering the growth of the market. Based on type of devices, the market can be segmented as follows: - Percutaneous thrombectomy devices - Embolectomy balloon catheters - Catheter-directed thrombolysis - IVCF - Neurovascular embolectomy devices Key vendors - AngioDynamics - Boston Scientific - Cook Group - Stryker Other prominent vendors - Acandis - Argon Medical Devices - Asid Bonz - Biosensors International Group - Control Medical Technology - Covidien - DePuy Synthes - Dispomedica - Edwards Lifesciences - EKOS (a BTG International Group company) - Eurocor - FBMedical-ISOMed - iVascular - LeMaitre Vascular - Merit Medical - Phenox - Straub Medical - Teleflex Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market overview 03.2 Product offerings 04. Market Research Methodology 04.1 Market research process 04.2 Research methodology 05. Introduction 05.1 Risk factors associated with blood clots 05.2 Epidemiology of VTE 05.3 Pathophysiology of VTE 05.4 Blood clot by type 06. Market Landscape 06.1 Market overview 06.2 Market size and forecast 06.3 Five forces analysis 07. Market Segmentation by Device 08. Geographical Segmentation 09. Americas 09.1 Market size and forecast 10. EMEA 10.1 Economic burden of VTE following major orthopedic surgery in Europe 10.2 Market size and forecast 11. APAC 11.1 Market size and forecast 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 19.1 Competitive scenario 19.1.1 Key news 19.1.2 Mergers and acquisitions 19.2 Market share analysis 2013 19.3 Other prominent vendors 20. Key Vendor Analysis 20.1 AngioDynamics 20.1.1 Key facts 20.1.2 Business overview 20.1.3 Business segmentation 20.1.4 Business strategy 20.1.5 Revenue segmentation by category of product 20.1.6 Revenue segmentation by geography 20.1.7 Key information 20.1.8 SWOT analysis 20.2 Boston Scientific 20.2.1 Key facts 20.2.2 Business Overview 20.2.3 Business segmentation 20.2.4 Business segmentation by revenue 2013 20.2.5 Business segmentation by revenue 2012 and 2013 20.2.6 Geographical segmentation by revenue 2013 20.2.7 Business strategy 20.2.8 Key developments 20.2.9 SWOT analysis 20.3 Cook Medical 20.3.1 Key facts 20.3.2 Business overview 20.3.3 Key divisions 20.3.4 Geographical segmentation 2013 20.3.5 Business strategy 20.3.6 Recent developments 20.3.7 SWOT analysis 20.4 Stryker 20.4.1 Key facts 20.4.2 Business overview 20.4.3 Business segmentation by revenue 2013 20.4.4 Business segmentation by revenue 2012 and 2013 20.4.5 Geographical segmentation by revenue 2013 20.4.6 Business strategy 20.4.7 Recent developments 20.4.8 SWOT analysis 21.Other Reports in this Series List of Exhibts: Exhibit 1: Market research methodology Exhibit 2: Risk factors associated with blood clots Exhibit 3: VTE incidences in US Exhibit 4: Other incidences Exhibit 5: Types of blood clot Exhibit 6: Risk factors for DVT Exhibit 7: Risk factors for PE Exhibit 8: Global clot management devices market 2014-2019 ($ million) Exhibit 9: Segmentation by device Exhibit 10: Segmentation of global clot management devices market by geography 2014 Exhibit 11: Clot management devices market 2014-2019 ($ million) Exhibit 12: VTE disease burden in Europe Exhibit 13: Total number of VTE events per year within six European countries Exhibit 14: Relative distribution of diagnosed and undiagnosed PE among fatal VTE events Exhibit 15: Clot management devices market 2014-2019 ($ million) Exhibit 16: Clot management devices market 2014-2019 ($ million) Exhibit 17: Segmentation of global clot management devices market by geography 2014-2019 Exhibit 18: Segmentation of global clot management devices market by geography 2014-2019 ($ million) Exhibit 19: Segmentation of global clot management devices market by geography 2014 and 2019 Exhibit 20: Segmentation of global clot management devices market by geography 2014 and 2019 ($ million) Exhibit 21: Endovascular treatment of stroke Exhibit 22: Clinical evidence Exhibit 23: AngioDynamics: business segmentation by category of product Exhibit 24: AngioDynamics: segmentation of revenue by category of product 2014 Exhibit 25: AngioDynamics: segmentation of revenue by geography 2014 Exhibit 26: Boston Scientific: business segmentation 2013 Exhibit 27: Boston Scientific: business segmentation by revenue 2013 Exhibit 28: Boston Scientific: business segmentation by revenue 2012 and 2013 ($ million) Exhibit 29: Boston Scientific: geographical segmentation by revenue 2013 Exhibit 30: Cook Medical: key divisions Exhibit 31: Cook Medical: geographical segmentation 2013 Exhibit 32: Stryker: business segmentation by revenue 2013 Exhibit 33: Stryker: business segmentation by revenue 2012 and 2013 ($ million) Exhibit 34: Stryker: geographical segmentation by revenue 2013 Companies Mentioned - AngioDynamics Inc - Boston Scientific Corp - Cook Medical - Stryker Corp. - Acandis GmbH & Co. KG - Argon Medical Devices - Asid Bonz - Biosensors International Group - Control Medical Technology - Covidien - DePuy Synthes - Dispomedica - Edwards Lifesciences - EKOS - a BTG International group company - Eurocor - FBMedical-ISOMed - iVascular - LeMaitre Vascular - Merit Medical Systems - Phenox GmbH - Straub Medical AG - Teleflex For more information visit http://www.researchandmarkets.com/research/xm...lobal_clot About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 17.42 (+0.31), LMAT: 11.22 (+0.01), EW: 153.96 (+1.24), MMSI: 25.64 (+0.46), SYK: 101.16 (+1.14)
Womenheart Announces 8 National Hospital Alliance Membership Grant Recipients To Advance Women's Heart Health In Underserved Communities
PR Newswire - Thu Jul 16, 1:09PM CDT
Thanks to a generous grant from the Edwards Lifesciences Foundation through its Every Heartbeat Matters initiative, WomenHeart: The National Coalition for Women with Heart Disease announced today that it has awarded eight National Hospital Alliance membership grants to hospitals in underserved communities to provide much-needed support and education to their women heart patients. The WomenHeart National Hospital Alliance (NHA) is the nation's only partnership program between WomenHeart and progressive hospitals committed to advancing women's heart health and gender specific cardiovascular care.
EW: 153.96 (+1.24)
Heart Valve Quickens Interest In Edwards Lifesciences
at Investor's Business Daily - Tue Jul 14, 4:41PM CDT
Artificial heart-valve pioneer Edwards Lifesciences still makes valves that are implanted the traditional way -- through open heart surgery. But smaller-profile transcatheter valves implanted through a catheter are making Edwards' (EW) pulse beat...
ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), STJ: 74.04 (+0.86), EW: 153.96 (+1.24)
Edwards Lifesciences to Host Earnings Conference Call on July 28, 2015
PR Newswire - Tue Jul 14, 9:00AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended June 30, 2015 after the market closes on Tuesday, July 28, 2015, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
EW: 153.96 (+1.24)
Edwards Lifesciences
at Investor's Business Daily - Mon Jul 13, 5:54PM CDT
Edwards Lifesciences (EW) hit a new high Mon. after its Fri. announcement that it was buying CardiAQ. RBC Capital Markets and Northland Capital Markets upgraded the heart-surgery giant to outperform. Shares rose 3.4% to 152.11.
EW: 153.96 (+1.24)
Big Cap 20: Biotech Red-Hot As Medicals Stay Dominant
at Investor's Business Daily - Mon Jul 13, 5:43PM CDT
Biotechs continue their rebound as medical-related stocks remain at center stage on this week's Big Cap 20, accounting for half the list. Edwards Lifesciences (EW) gapped up past a 147.40 cup-with-handle buy point initially cleared Tuesday. RBC...
HCA: 92.34 (+0.31), VRX: 257.53 (+0.23), WBA: 95.88 (+1.50), GILD: 112.81 (+2.27), UNH: 120.30 (+2.42), ALXN: 202.69 (+4.59), EW: 153.96 (+1.24), ILMN: 217.61 (+0.34), ABBV: 70.83 (+1.49), CELG: 135.70 (+3.14)
Look for Shares of Edwards Lifesciences to Potentially Pullback after Yesterday's 3.36% Rise
Comtex SmarTrend(R) - Mon Jul 13, 4:58PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $149.82 to a high of $152.90. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $148.45 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 153.96 (+1.24)
The Best Stocks in Medical Devices Are Kicking It Overseas
Cheryl Swanson, The Motley Fool - Motley Fool - 36 mins ago
Source: Flickr/Anders Sandher. Looking for medical-device stocks with solid fundamentals and long-term growth drivers? Then train your eyes overseas. With apologies to Shakespeare, the world is the medical-device industry's new oyster. While...
MDT: 77.19 (+1.53), EW: 153.96 (+1.24)
5 Health Care Stocks to Trade for Gains -- Must-See Charts
at The Street - 50 mins ago
Health care stocks have been persistent outperformers in 2015. Here are five to trade now.
GILD: 112.79 (+2.25), UTHR: 168.27 (+2.49), SHPG: 262.93 (+3.82), EW: 153.96 (+1.24), IDXX: 65.67 (-0.63)
Edwards Lifesciences Set to Possibly Rebound After Yesterday's Selloff of 1.53%
Comtex SmarTrend(R) - Mon Jul 27, 5:15PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $151.90 to a high of $154.75. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $154.70 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EW: 153.96 (+1.24)
Meet 5 IBD 50 Stocks Reporting Earnings This Week
at Investor's Business Daily - Sat Jul 25, 9:02AM CDT
Earnings season has kicked into high gear, and a number of top-rated stocks such as Vasco Data Security (VDSI) and Facebook (FB) are due to report earnings this coming week. The computer-generated IBD 50 list of premier stocks is based on a...
VDSI: 25.62 (+0.50), ELLI: 70.59 (-1.04), GILD: 112.79 (+2.25), FB: 94.89 (+0.72), ORLY: 241.48 (+1.64), UTHR: 168.27 (+2.49), EW: 153.96 (+1.24), CRI: 108.41 (+1.71), TASR: 30.59 (+0.26)
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market
at Investor's Business Daily - Fri Jul 24, 6:14PM CDT
A handful of IBD 50 stocks got a boost last week, bucking overall market weakness, thanks to better-than-expected quarterly results. Illumina (ILMN), which makes genetic testing equipment, was among the few disappointments. It plunged 8% Wednesday...
VRX: 257.53 (+0.23), ELLI: 70.59 (-1.04), FB: 94.89 (+0.72), UHS: 141.22 (+0.93), UTHR: 168.27 (+2.49), ORLY: 241.48 (+1.64), EW: 153.96 (+1.24), ILMN: 217.61 (+0.34), MANH: 64.38 (-0.57), SBUX: 57.10 (+0.12), VDSI: 25.62 (+0.50), CRUS: 34.08 (+1.18), TASR: 30.59 (+0.26), AAPL: 123.47 (+0.70)
New Cardiac Devices Get Investors' Hearts Pumping
at Investor's Business Daily - Fri Jul 24, 2:16PM CDT
A hot new technology. A widespread, deadly disease. A whole lot of money changing hands. That was the story last Wednesday when St. Jude Medical (STJ) agreed to pay $3.4 billion in cash for Thoratec (THOR), developer of an implant called the left...
BSX: 17.42 (+0.31), ABT: 50.97 (+0.28), ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), CAH: 83.34 (+1.05), LMAT: 11.22 (+0.01), EW: 153.96 (+1.24), STJ: 74.04 (+0.86), THOR: 63.07 (-0.16), VASC: 38.03 (-0.10), HTWR: 81.08 (-1.67), MMSI: 25.64 (+0.46)
The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters) to 2019
M2 - Fri Jul 24, 8:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8qwd2/the_world_market) has announced the addition of the "The World Market for Catheters (Urological, Intravenous, Cardiovascular Intervention, Angiography, Dialysis, PTCA, PICC, Oximetry and Surgical Catheters)" report to their offering. Among the catheters used in urological applications are the Foley and the urethral catheters. Cardiovascular catheters find use in cardiac catheterization. Angiography catheters are used in cardiological diagnostics. Intravenous catheters are used if a person requires frequent or continuous injections of medications or fluids for nutritional support. A wound drain catheter is inserted while a patient is in the operating room receiving general anesthesia All of these catheters are included in this report. For many of these segments, company market share and regional breakout for US, Europe and Rest of World is provided. In addition to numbers that can be useful for business planning, the report provides analysis of the industry, including analysis of several important trends. Increased life expectancy and subsequent aging of the global population play a key role in the rising demand for all types of medical catheters. Companies seeking opportunities in this medical device market will want to utilize Kalorama Information's World Market for Catheters. This report contains global market size and forecast to 2019 for the following types of catheters: - Foley Catheters - Urethral Catheters - PTCA Catheters - Dialysis Catheters - Atherectomy Catheters - Ablation Catheters - Cardiac Angiography Catheters - Peripheral Angiography Catheters - Implantable Ports - Central Venous Catheters - Peripheral Insertion Catheters - Peripherally Inserted Central Catheters - Peripheral Insertion Midline Catheters - Oximetry Catheters - Thermodilution Catheters - Suction Catheters - Wound Drainage Catheters Trends discussed in this report include the following: - Infection and Control - Vascular - Urinary - Catheter Intervention Trends - Catheter Malfunction - Antimicrobial Lock Solutions - Stroke Treatment - MRI Catheters - Sinus Balloon Catheter - Interventional Radiology - Heart Patch - PFO - New And Alternative Materials - Antiseptic-Coated Catheters Company profiles are included, with profiles of the following companies: - Abbott Laboratories - Angio Dynamics - Atrium Medical - Bactiguard Ab - C.R. Bard - Becton Dickinson - Boston Scientific - B. Braun Melsungen - Cardinal Health - Carmeda - Cook Group - Catheter Research Inc. - Covidien - Edwards Lifesciences - Greatbatch Medical - Johnson &Johnson - Flexicath - Hansen Medical - Iapyx Medical - Integra Lifesciences Holdings - Irvine Scientific - Medtronic - Medcomp - Siemens Medical Solutions - Smiths Medical - St.Jude Medical - Teleflex Medical Company - Terumo - Vascular Solutions - Vesta Inc. - Volcano Corp. - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/v8...rld_market
ZMH: 113.56 (+0.29), BSX: 17.42 (+0.31), ABT: 50.97 (+0.28), MDT: 77.19 (+1.53), HNSN: 0.88 (-0.02), VOLC: 17.99 (+0.01), EW: 153.96 (+1.24), VASC: 38.03 (-0.10)
What's in Store for Edwards Lifesciences (EW) in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 5:14PM CDT
Last quarter, Edwards Lifesciences (EW) had delivered a positive earnings surprise of 7.69%
ZLTQ: 32.26 (+0.89), EW: 153.96 (+1.24), AMED: 43.79 (+0.35), XRAY: 52.13 (+0.53)
Breakout Watch: Abiomed Pumps Up Before Earnings
at Investor's Business Daily - Thu Jul 23, 10:39AM CDT
Heart pump maker Abiomed (ABMD) is closing in on a buy point as it gets ready to report Q2 earnings Aug. 4. With a mission of "recovering hearts and saving lives," Abiomed developed the Impella 2.5, which it bills as the world's smallest heart pump....
ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), STJ: 74.04 (+0.86), EW: 153.96 (+1.24), THOR: 63.07 (-0.16)
SmarTrend Watching for Potential Pullback in Shares of Edwards Lifesciences After 1.35% Gain
Comtex SmarTrend(R) - Tue Jul 21, 4:44PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $153.82 to a high of $156.49. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $155.03 on volume of 909,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 153.96 (+1.24)
Cramer Says Investors Who Missed Google, Facebook, Netflix Runs Now Have to Wait
at The Street - Tue Jul 21, 4:24PM CDT
Jim Cramer answered viewers' Twitter questions on matters including popular stocks, commodities and gold.
ABMD: 73.05 (+0.33), FB: 94.88 (+0.71), GOLD: 59.28 (+1.69), EW: 153.96 (+1.24), GOOG: 627.05 (-0.21), NFLX: 107.53 (+1.10), T: 34.38 (+0.06), STJ: 74.04 (+0.86), TMUS: 36.99 (+0.49), TWTR: 35.95 (+1.25), VZ: 45.82 (-0.01), AAPL: 123.47 (+0.70)
Edwards Lifesciences Shares Up 16.6% Since SmarTrend's Buy Recommendation (EW)
Comtex SmarTrend(R) - Tue Jul 21, 11:01AM CDT
SmarTrend identified an Uptrend for Edwards Lifesciences (NYSE:EW) on June 9th, 2015 at $133.64. In approximately 1 month, Edwards Lifesciences has returned 16.61% as of today's recent price of $155.84.
EW: 153.96 (+1.24)
Global Clot Management Devices Market 2015-2019 with AngioDynamics, Boston Scientific, Cook Group & Stryker Dominating
M2 - Mon Jul 20, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xm9gtt/global_clot) has announced the addition of the "Global Clot Management Devices Market 2015-2019" report to their offering. The global clot management devices market to grow at a CAGR of 5.95% over the period 2014-2019. A blood clot or thrombus is the end stage of blood coagulation process in hemostasis. Blood clot is the body's response to an injury to prevent bleeding. However, a clot can be harmful when it forms abnormally to obstruct blood flow through healthy blood vessels. This condition is called thrombosis. A blood clot in arteries can lead to heart attack, while blood clot formed in the deep veins can lead to DVT or PE. Clot management devices help in the removal of a clot or dissolving clot in the blood vessels. The report, the Global Clot Management Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it also covers the global clot management devices market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. One of the trends is the increased number of MIS procedures. Surgical procedures expose a patient's blood to foreign surfaces, which may initiate coagulation. DVT and PE are some major complications faced by patients who undergo surgery. MIS reduces patient trauma and recovery time. According to the report, a rise in awareness of endovascular treatment is one of the primary drivers in this market. Endovascular treatment is a surgical treatment in which microcatheters, embolic coils, and stents are used to remove blood clots. Further, the report states that the high acceptance of anticoagulant therapy is hindering the growth of the market. Based on type of devices, the market can be segmented as follows: - Percutaneous thrombectomy devices - Embolectomy balloon catheters - Catheter-directed thrombolysis - IVCF - Neurovascular embolectomy devices Key vendors - AngioDynamics - Boston Scientific - Cook Group - Stryker Other prominent vendors - Acandis - Argon Medical Devices - Asid Bonz - Biosensors International Group - Control Medical Technology - Covidien - DePuy Synthes - Dispomedica - Edwards Lifesciences - EKOS (a BTG International Group company) - Eurocor - FBMedical-ISOMed - iVascular - LeMaitre Vascular - Merit Medical - Phenox - Straub Medical - Teleflex Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market overview 03.2 Product offerings 04. Market Research Methodology 04.1 Market research process 04.2 Research methodology 05. Introduction 05.1 Risk factors associated with blood clots 05.2 Epidemiology of VTE 05.3 Pathophysiology of VTE 05.4 Blood clot by type 06. Market Landscape 06.1 Market overview 06.2 Market size and forecast 06.3 Five forces analysis 07. Market Segmentation by Device 08. Geographical Segmentation 09. Americas 09.1 Market size and forecast 10. EMEA 10.1 Economic burden of VTE following major orthopedic surgery in Europe 10.2 Market size and forecast 11. APAC 11.1 Market size and forecast 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 19.1 Competitive scenario 19.1.1 Key news 19.1.2 Mergers and acquisitions 19.2 Market share analysis 2013 19.3 Other prominent vendors 20. Key Vendor Analysis 20.1 AngioDynamics 20.1.1 Key facts 20.1.2 Business overview 20.1.3 Business segmentation 20.1.4 Business strategy 20.1.5 Revenue segmentation by category of product 20.1.6 Revenue segmentation by geography 20.1.7 Key information 20.1.8 SWOT analysis 20.2 Boston Scientific 20.2.1 Key facts 20.2.2 Business Overview 20.2.3 Business segmentation 20.2.4 Business segmentation by revenue 2013 20.2.5 Business segmentation by revenue 2012 and 2013 20.2.6 Geographical segmentation by revenue 2013 20.2.7 Business strategy 20.2.8 Key developments 20.2.9 SWOT analysis 20.3 Cook Medical 20.3.1 Key facts 20.3.2 Business overview 20.3.3 Key divisions 20.3.4 Geographical segmentation 2013 20.3.5 Business strategy 20.3.6 Recent developments 20.3.7 SWOT analysis 20.4 Stryker 20.4.1 Key facts 20.4.2 Business overview 20.4.3 Business segmentation by revenue 2013 20.4.4 Business segmentation by revenue 2012 and 2013 20.4.5 Geographical segmentation by revenue 2013 20.4.6 Business strategy 20.4.7 Recent developments 20.4.8 SWOT analysis 21.Other Reports in this Series List of Exhibts: Exhibit 1: Market research methodology Exhibit 2: Risk factors associated with blood clots Exhibit 3: VTE incidences in US Exhibit 4: Other incidences Exhibit 5: Types of blood clot Exhibit 6: Risk factors for DVT Exhibit 7: Risk factors for PE Exhibit 8: Global clot management devices market 2014-2019 ($ million) Exhibit 9: Segmentation by device Exhibit 10: Segmentation of global clot management devices market by geography 2014 Exhibit 11: Clot management devices market 2014-2019 ($ million) Exhibit 12: VTE disease burden in Europe Exhibit 13: Total number of VTE events per year within six European countries Exhibit 14: Relative distribution of diagnosed and undiagnosed PE among fatal VTE events Exhibit 15: Clot management devices market 2014-2019 ($ million) Exhibit 16: Clot management devices market 2014-2019 ($ million) Exhibit 17: Segmentation of global clot management devices market by geography 2014-2019 Exhibit 18: Segmentation of global clot management devices market by geography 2014-2019 ($ million) Exhibit 19: Segmentation of global clot management devices market by geography 2014 and 2019 Exhibit 20: Segmentation of global clot management devices market by geography 2014 and 2019 ($ million) Exhibit 21: Endovascular treatment of stroke Exhibit 22: Clinical evidence Exhibit 23: AngioDynamics: business segmentation by category of product Exhibit 24: AngioDynamics: segmentation of revenue by category of product 2014 Exhibit 25: AngioDynamics: segmentation of revenue by geography 2014 Exhibit 26: Boston Scientific: business segmentation 2013 Exhibit 27: Boston Scientific: business segmentation by revenue 2013 Exhibit 28: Boston Scientific: business segmentation by revenue 2012 and 2013 ($ million) Exhibit 29: Boston Scientific: geographical segmentation by revenue 2013 Exhibit 30: Cook Medical: key divisions Exhibit 31: Cook Medical: geographical segmentation 2013 Exhibit 32: Stryker: business segmentation by revenue 2013 Exhibit 33: Stryker: business segmentation by revenue 2012 and 2013 ($ million) Exhibit 34: Stryker: geographical segmentation by revenue 2013 Companies Mentioned - AngioDynamics Inc - Boston Scientific Corp - Cook Medical - Stryker Corp. - Acandis GmbH & Co. KG - Argon Medical Devices - Asid Bonz - Biosensors International Group - Control Medical Technology - Covidien - DePuy Synthes - Dispomedica - Edwards Lifesciences - EKOS - a BTG International group company - Eurocor - FBMedical-ISOMed - iVascular - LeMaitre Vascular - Merit Medical Systems - Phenox GmbH - Straub Medical AG - Teleflex For more information visit http://www.researchandmarkets.com/research/xm...lobal_clot About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 17.42 (+0.31), LMAT: 11.22 (+0.01), EW: 153.96 (+1.24), MMSI: 25.64 (+0.46), SYK: 101.16 (+1.14)
Womenheart Announces 8 National Hospital Alliance Membership Grant Recipients To Advance Women's Heart Health In Underserved Communities
PR Newswire - Thu Jul 16, 1:09PM CDT
Thanks to a generous grant from the Edwards Lifesciences Foundation through its Every Heartbeat Matters initiative, WomenHeart: The National Coalition for Women with Heart Disease announced today that it has awarded eight National Hospital Alliance membership grants to hospitals in underserved communities to provide much-needed support and education to their women heart patients. The WomenHeart National Hospital Alliance (NHA) is the nation's only partnership program between WomenHeart and progressive hospitals committed to advancing women's heart health and gender specific cardiovascular care.
EW: 153.96 (+1.24)
Heart Valve Quickens Interest In Edwards Lifesciences
at Investor's Business Daily - Tue Jul 14, 4:41PM CDT
Artificial heart-valve pioneer Edwards Lifesciences still makes valves that are implanted the traditional way -- through open heart surgery. But smaller-profile transcatheter valves implanted through a catheter are making Edwards' (EW) pulse beat...
ABMD: 73.05 (+0.33), MDT: 77.19 (+1.53), STJ: 74.04 (+0.86), EW: 153.96 (+1.24)
Edwards Lifesciences to Host Earnings Conference Call on July 28, 2015
PR Newswire - Tue Jul 14, 9:00AM CDT
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended June 30, 2015 after the market closes on Tuesday, July 28, 2015, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
EW: 153.96 (+1.24)
Edwards Lifesciences
at Investor's Business Daily - Mon Jul 13, 5:54PM CDT
Edwards Lifesciences (EW) hit a new high Mon. after its Fri. announcement that it was buying CardiAQ. RBC Capital Markets and Northland Capital Markets upgraded the heart-surgery giant to outperform. Shares rose 3.4% to 152.11.
EW: 153.96 (+1.24)
Big Cap 20: Biotech Red-Hot As Medicals Stay Dominant
at Investor's Business Daily - Mon Jul 13, 5:43PM CDT
Biotechs continue their rebound as medical-related stocks remain at center stage on this week's Big Cap 20, accounting for half the list. Edwards Lifesciences (EW) gapped up past a 147.40 cup-with-handle buy point initially cleared Tuesday. RBC...
HCA: 92.34 (+0.31), VRX: 257.53 (+0.23), WBA: 95.88 (+1.50), GILD: 112.81 (+2.27), UNH: 120.30 (+2.42), ALXN: 202.69 (+4.59), EW: 153.96 (+1.24), ILMN: 217.61 (+0.34), ABBV: 70.83 (+1.49), CELG: 135.70 (+3.14)
Look for Shares of Edwards Lifesciences to Potentially Pullback after Yesterday's 3.36% Rise
Comtex SmarTrend(R) - Mon Jul 13, 4:58PM CDT
Edwards Lifesciences (NYSE:EW) traded in a range yesterday that spanned from a low of $149.82 to a high of $152.90. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $148.45 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EW: 153.96 (+1.24)
